A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
N/A
18 Years
70 Years
18 Years
70 Years
Open (Enrolling)
Female
Recurrent Ovarian Cancer
Female
Recurrent Ovarian Cancer
Trial Information
A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
Inclusion Criteria:
1. age between 18 and 70 years old
2. singed the information consent form
3. Expected survival time >3 months
4. Recurrence for at least 6 months after receiving initial platinum-based chemotherapy
and without cytoreductive surgery indications.
Exclusion Criteria:
1. Recurrence within 6 months after receiving initial platinum-based chemotherapy
2. without radiographic evidence for tumor recurrence
3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
Evidence of the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
Outcome Description:
Blood routine, urine routine, hepatic and kidney function, electrolyte, ECG, CT,MRI
Outcome Time Frame:
from pre-chemotherapy to 4-6 weeks post-chemotherapy
Safety Issue:
Yes
Principal Investigator
Hong-bing Cai, MD,PhD
Investigator Role:
Study Director
Investigator Affiliation:
Wuhan University
Authority:
China: Ethics Committee
Study ID:
CHB2013
NCT ID:
NCT01851746
Start Date:
March 2013
Completion Date:
February 2015
Related Keywords:
- Recurrent Ovarian Cancer
- recurrent ovarian cancer
- lobaplatin
- docetaxel
- carboplatin
- Ovarian Neoplasms
Name | Location |
|---|
